ATE355057T1 - Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen - Google Patents

Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen

Info

Publication number
ATE355057T1
ATE355057T1 AT96901620T AT96901620T ATE355057T1 AT E355057 T1 ATE355057 T1 AT E355057T1 AT 96901620 T AT96901620 T AT 96901620T AT 96901620 T AT96901620 T AT 96901620T AT E355057 T1 ATE355057 T1 AT E355057T1
Authority
AT
Austria
Prior art keywords
amino acids
disorders
movement disorders
aromatic
branched amino
Prior art date
Application number
AT96901620T
Other languages
English (en)
Inventor
Mary Ann Richardson
Original Assignee
New York State Office Of Menta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23462994&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE355057(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by New York State Office Of Menta filed Critical New York State Office Of Menta
Application granted granted Critical
Publication of ATE355057T1 publication Critical patent/ATE355057T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96901620T 1995-01-11 1996-01-11 Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen ATE355057T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/371,211 US5670539A (en) 1993-07-21 1995-01-11 Treatment of movement disorders using large neutral amino acids

Publications (1)

Publication Number Publication Date
ATE355057T1 true ATE355057T1 (de) 2006-03-15

Family

ID=23462994

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96901620T ATE355057T1 (de) 1995-01-11 1996-01-11 Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen

Country Status (6)

Country Link
US (2) US5670539A (de)
EP (1) EP0799034B1 (de)
AT (1) ATE355057T1 (de)
CA (1) CA2210233A1 (de)
DE (1) DE69636934D1 (de)
WO (1) WO1996021437A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200758B1 (en) 1999-02-19 2001-03-13 New York State Office Of Mental Health Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
US20030185754A1 (en) * 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US20030166554A1 (en) * 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US6458804B1 (en) 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US6620850B2 (en) * 2001-09-19 2003-09-16 University Of Florida Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
WO2004016261A1 (en) * 2002-08-12 2004-02-26 Yuuichi Murayama Method for suppressing proliferation of abnormal prion protein with leucine, isoleucine or valine
EP1575501A2 (de) * 2002-07-12 2005-09-21 University of Rochester VERWENDUNG VON AMINOSûUREN ZUR BEHANDLUNG VERSCHIEDENER ERKRANKUNGEN
EP1572188A1 (de) * 2002-12-13 2005-09-14 Warner-Lambert Company LLC Pregabalin-derivate zur behandlung vonfibromyalgie und anderen erkrankungen
JP4651078B2 (ja) * 2003-03-10 2011-03-16 雅美 森山 異常プリオン蛋白質の増殖の抑制方法
ITTO20030789A1 (it) * 2003-10-07 2005-04-08 Professional Dietetics Srl Composizione a base di amino acidi per il trattamento
EP2237777A4 (de) * 2008-01-02 2011-03-30 Marine Bio Co Ltd Zusammensetzungen und verfahren zur behandlung neurodegenerativer erkrankungen
WO2014152917A2 (en) * 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv Physiological ligands for gpr139

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100293A (en) * 1974-04-15 1978-07-11 The Johns Hopkins University Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids
US4138484A (en) * 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US4129652A (en) * 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
US4320146A (en) * 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4296119A (en) * 1978-04-24 1981-10-20 Massachusetts Institute Of Technology Process and composition for reducing blood pressure in animals
US4209531A (en) * 1978-09-13 1980-06-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4252822A (en) * 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4438144A (en) * 1980-07-31 1984-03-20 Blackburn George L Amino acid preparation and therapy for treatment of stress and injury
US4355044A (en) * 1980-12-19 1982-10-19 Bernardo Heller D-Phenylalanine treatment
US4687782A (en) * 1984-12-10 1987-08-18 Nutri-Fuels Systems, Inc. Nutritional composition for enhancing skeletal muscle adaptation to exercise training
DE3519687A1 (de) * 1985-06-01 1986-12-04 Veit Arend Aminosaeuren enthaltendes arzneimittel
US4780475A (en) * 1986-02-03 1988-10-25 Cerra Frank B Preparation for the prevention of catabolism
US4837219A (en) * 1987-11-05 1989-06-06 Jeffrey Hutterer Medication for Alzheimer's disease
US5028622A (en) * 1988-05-06 1991-07-02 Ajinomoto Company, Inc. Administration of amino acids as treatment for neurodegenerative disorders
US5006559A (en) * 1988-08-31 1991-04-09 Clintec Nutrition Co. Method of use of branched-chain amino acids infusions to influence appetite
US5206218A (en) * 1989-04-03 1993-04-27 Interneuron Pharmaceuticals, Inc. Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acids (lnaa)
US5026721A (en) * 1989-06-05 1991-06-25 Dudrick Stanley J Amino acid nutritional supplement and regimen for enhancing physical performance through sound nutrition
US5017616A (en) * 1989-11-30 1991-05-21 Jeffrey Askanazi Method for improving ventilation during sleep and treating sleep related ventilation abnormalities
US5256697A (en) * 1992-04-16 1993-10-26 Abbott Laboratories Method of administering pyruvate and methods of synthesizing pyruvate precursors
US5256669A (en) * 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
US5393784A (en) * 1993-07-21 1995-02-28 New York State Office Of Mental Health Treatment of tardive dyskinesia with leucine, isoleucine, valine or mixtures thereof

Also Published As

Publication number Publication date
EP0799034A4 (de) 2002-05-22
WO1996021437A1 (en) 1996-07-18
CA2210233A1 (en) 1996-07-18
US5919823A (en) 1999-07-06
EP0799034B1 (de) 2007-02-28
EP0799034A1 (de) 1997-10-08
DE69636934D1 (de) 2007-04-12
US5670539A (en) 1997-09-23

Similar Documents

Publication Publication Date Title
ATE355057T1 (de) Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen
HU9600832D0 (en) Inhibitors of beta-amyloid protein production
DE60042137D1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
ATE266417T1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
WO2000047618A3 (en) HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES
MXPA03010911A (es) Anticuerpos contra ngf para el tratamiento de varios desordenes.
ATE407573T1 (de) Verwendung von lokal verabreichten lysine zur verbesserung der vaskularen funktion
HUT65754A (en) Process for production of preparations containing complement inhibitors for treatment of inflammatory intestinal-and dermal-diseases
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
HU9502585D0 (en) Use of riluzole for treating aids-related neural disorders
ATE254924T1 (de) Stör-notokord zur verminderung der symptome / behandlung von arthritis
IL129178A0 (en) Induction of nerve generation
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
DE69426471D1 (de) Verwendung von Sulodexid und von Arzneimitteln, die dieses enthalten, zur Behandlung der diabetischen Nephropathie
AUPP674898A0 (en) A method of treatment
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69821970D1 (de) Verwendung von CITICOLINE ZUR BEHANDLUNG VON MULTIPLER SKLEROSE
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
PL329219A1 (en) Application of benzonaphtene derivatives in production of drugs for treating nervous system diseases
DE60107516D1 (de) Verwendung von Pregabalin zur Asthma Behandlung
MXPA02011162A (es) Proteina cln2 recombinante de humano y metodos para su reduccion y uso.
ATE209005T1 (de) Verwendung von threonin zur behandlung der phenylketonurie
DE59809592D1 (de) Verwendung von putamen ovi
WO2000030669A3 (en) Use of plasma phospholipid transfer proteins in treating cardiovascular dieases

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties